Abstract
Since the manufacture of the first biotech product for a fledgling biopharmaceutical industry in 1982, Escherichia coli, has played an important role in the industrial production of recombinant proteins. It is now 40 years since the introduction of Humulin® for the treatment of diabetes. E. coli remains an important production host, its use as a cell factory is well established and it has become the most popular expression platform particularly for non-glycosylated therapeutic proteins. A number of significant inherent obstacles in the use of prokaryotic expression systems to produce biologics has always restricted production. These include codon usage, the absence of post-translational modifications and proteolytic processing at the cell envelope. In this review, we reflect on the contribution that this model organism has made in the production of new biotech products for human medicine. This will include new advancements in the E. coli expression system to meet the biotechnology industry requirements, such as novel engineered strains to glycosylate heterologous proteins, add disulphide bonds and express complex proteins. The biopharmaceutical market is growing rapidly, with two production systems competing for market dominance: mammalian cells and microorganisms. In the past 10 years, with increased growth of antibody-based therapies, mammalian hosts particularly CHO cells have dominated. However, with new antibody like scaffolds and mimetics emerging as future proteins of interest, E. coli has again the opportunity to be the selected as the production system of choice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arya R, Sabir JSM, Bora RS, Saini KS (2015) Optimization of culture parameters and novel strategies to improve protein solubility. In: Fruitos EG (ed) EeInsoluble proteins: methods and protocols. Methods in molecular biology series, vol 1258, pp 45–63. Springer, New York
Assadi-Porter FM, Patry S, Markley JL (2008) Efficient and rapid protein expression and purification of small high disulfide containing sweet protein brazzein in E. coli. Protein Expr Purif 58:263–268. https://doi.org/10.1016/j.pep.2007.11.009
Bachmann BJ (1996) Derivations and genotypes of some mutant derivatives of Escherichia coli K-12. In: Neidhardt, (ed) Escherichia coli and Salmonella, 2nd edn. ASM Press, Washington DC, pp p2460-2488
Baeshen MN, Al-Hejin AM, Bora RS, Ahmed MMM, Ramadan HAI, Saini KS, Baeshen NA, Redwan EM (2015) Production of biopharmaceuticals in E. coli: Current scenario and future perspectives. J Microbiol Biotechnol 25:953–962. https://doi.org/10.4014/jmb.1412.12079
Bhatwa A, Wang W, Hassan Y, Abraham N, Li XZ, Zhou T (2021) Challenges associated with the formation of recombinant protein inclusion bodies in Escherichia coli and strategies to address them for industrial applications. Front Bioeng Biotechnol. https://doi.org/10.3389/fbioe.2021.630551
Bhawsinghka N, Glenn KF, Schaaper RM (2020) Complete genome sequence of Escherichia coli BL21-AI. Microbiol Resour Announc 9(10):e00009-20. https://doi.org/10.1128/MRA.00009-20
Binz HK, Bakker TR, Phillips DJ, Cornelius A, Zitt C, Göttler T, Sigrist G, Fiedler U, Ekawardhani S, Dolado I, Saliba JA, Tresch G, Proba K, Stumpp MT (2017) Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin® drug candidate. Mabs 9:1262–1269. https://doi.org/10.1080/19420862.2017.1305529
Blount ZD (2015) The unexhausted potential of E. coli. Elife 4:e05826. https://doi.org/10.7554/eLife.05826
Browning DF, Richards KL, Peswani AR et al (2017) Escherichia coli “TatExpress” strains super-secrete human growth hormone into the bacterial periplasm by Tat pathway. Biotechnol Bioeng 114:2828–2836. https://doi.org/10.1002/bit.26434
Bui LA, Hurst S, Finch GL et al (2015) Key considerations in the preclinical development of biosimilars. Drug Discov Today 20:3–15. https://doi.org/10.1016/j.drudis.2015.03.011
Castiñeiras TS, Williams SG, Hitchcock AG, Smith DC (2018) E. coli strain engineering for the production of advanced biopharmaceutical products. FEMS Microbiol Lett. https://doi.org/10.1093/femsle/fny162
Chin JW (2017) Expanding and reprogramming the genetic code. Nature 550:53–60
Crane JM, Randall LL (2017) The sec system: Protein export in Escherichia coli. EcoSal Plus. https://doi.org/10.1128/ecosalplus.ESP-0002-2017
Crick FH, Barnett L, Brenner S, Watts-Tobin RJ (1961) General nature of the genetic code for proteins. Nature 192:1227–1232. https://doi.org/10.1038/1921227a0
Daegelen P, Studier FW, Lenski RE, Cure S, Kim JF (2009) Tracing ancestors and relatives of Escherichia coli B, and the derivation of B strains REL606 and BL21(DE3). J Mol Biol 394:634–43. https://doi.org/10.1016/j.jmb.2009.09.022
Dang G, Cao J, Cui Y et al (2016) Characterization of Rv0888, a novel extracellular nuclease from mycobacterium tuberculosis. Sci Rep 6:19033. https://doi.org/10.1038/srep19033
Dieci G, Bottarelli L, Ballabeni A, Ottonello S (2000) tRNA assisted overproduction of eukaryotic ribosomal proteins. Prot Expr Purif 18:346–354. https://doi.org/10.1006/prep.2000.1203
DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012
Du T, Buenbrazo N, Kell L, Rahmani S, Sim L, Withers SG, DeFrees S, Wakarchuk WA (2019) Bacterial expression platform for production of therapeutic proteins containing human-like O-linked glycans. Cell Chem Biol. 26:203–212. https://doi.org/10.1016/j.chembiol.2018.10.017
El Hajjajii H, Collet JF (2009) Disulfide bond formation. In: Walsh G (ed) Post-translational modification of protein biopharmaceuticals. Wiley Blackwell, New York, pp 277–294
Elleuche S, Qoura FM, Lorenz U, Rehn T, Brück T, Antranikian G (2015) Cloning, expression and characterization of the recombinant cold-active type-I pullulanase from Shewanella arctica. J Mol Catal B Enzym 116:70–77. https://doi.org/10.1016/j.molcatb.2015.03.001
European Medicines Agency Assessment Report EMA/CHMP/406682/2019 Committee for medicinal products for human use (CHMP) https://www.ema.europa.eu/en/documents/variation-report/lucentis-h-c-715-ii-0074-g-epar-assessment-report-variation_en.pdf
Fathi-Roudsari M, Akhavian-Tehrani A, Maghsoudi N (2016) Comparison of three Escherichia coli strains in recombinant production of reteplase. Avicenna J Med Biotechnol 8:16–22
Fredens J, Wang K, de la Torre D, Funke LFH, Robertson WE, Christova Y, Chia T, Schmied WH, Dunkelmann DL, Beránek V, Uttamapinant C, Llamazares AG, Elliott TS, Chin JW (2019) Total synthesis of Escherichia coli with a recoded genome. Nature 569:514–518. https://doi.org/10.1038/s41586-019-1192-5
Gvritishvili AG, Leung KW, Tombran-Tink J (2010) Codon preference optimization increases heterologous PEDF expression. PLoS One 5(11):e15056. https://doi.org/10.1371/journal.pone.0015056
Hartinger D, Heinl S, Schwartz H, Grabherr R, Schatzmayr G, Haltrich D et al (2010) Enhancement of solubility in Escherichia coli and purification of an aminotransferase from Sphingopyxis sp. MTA144 for deamination of hydrolyzed fumonisin B1. Microb Cell Fact 9:62. https://doi.org/10.1186/1475-2859-9-62
Hatahet F, Nguyen VD, Salo KE et al (2010) Disruption of reducing pathways is not essential for efficient disulfide bond formation in the cytoplasm of E. coli. Microb Cell Fact 9:67. https://doi.org/10.1186/1475-2859-9-67
Hausjell J, Weissensteiner J, Molitor C et al (2018) E. coli HMS174(DE3) is a sustainable alternative to BL21(DE3). Microb Cell Fact 17:169. https://doi.org/10.1186/s12934-018-1016-6
Heyde SAH, Nørholm MHH (2021) Tailoring the evolution of BL21(DE3) uncovers a key role for RNA stability in gene expression toxicity. Commun Biol 4:963. https://doi.org/10.1038/s42003-021-02493-4
Hofer M, Bönsch K, Greiner-Stöffele T, Ballschmiter M (2011) Characterization and engineering of a novel pyrroloquinoline quinone dependent glucose dehydrogenase from Sorangium cellulosum So ce56. Mol Biotechnol 47:253–261. https://doi.org/10.1007/s12033-010-9339-5
Hu XP, Dourado H, Schubert P et al (2020) The protein translation machinery is expressed for maximal efficiency in Escherichia coli. Nat Commun 11:5260. https://doi.org/10.1038/s41467-020-18948-x
Huang CJ, Lin H, Yang X (2012) Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements. J Ind Microbiol Biotechnol 39:383–399. https://doi.org/10.1007/s10295-011-1082-9
Huleani S, Roberts MR, Beales L, Papaioannou EH (2021) Escherichia coli as an antibody expression host for the production of diagnostic proteins: significance and expression Crit Rev. Biotech 1:18. https://doi.org/10.1080/07388551.2021.1967871
Isaacs FJ, Carr PA, Wang HH, Lajoie MJ, Sterling B, Kraal L, Tolonen AC, Gianoulis TA, Goodman DB, Reppas NB, Emig CJ, Bang D, Hwang SJ, Jewett MC, Jacobson JM, Church GM (2011) Precise manipulation of chromosomes in vivo enables genome-wide codon replacement. Science 333:348–353. https://doi.org/10.1126/science.1205822
Jacob F, Monod J (1961) Genetic regulatory mechanisms in the synthesis of proteins. J Mol Biol 3:318–356. https://doi.org/10.1016/S0022-2836(61)80072-7
Jeong H, Barbe V, Lee CH, Vallenet D, Yu DS, Choi SH, Couloux A, Lee SW, Yoon SH, Cattolico L, Hur CG, Park HS, Segurens B, Kim SC, Oh TK, Lenski RE, Studier FW, Daegelen P, Kim JF (2009) Genome sequences of Escherichia coli B strains REL606 and BL21(DE3). J Mol Biol 394:644–652. https://doi.org/10.1016/j.jmb.2009.09.052
Jiang C, Wynne M, Huber D (2021) How quality control systems AID sec-dependent protein translocation. Front Mol Biosci 8:669376. https://doi.org/10.3389/fmolb.2021.669376
Johnson IS (1983) Human insulin from recombinant DNA technology. Science 219(4585):632–637. https://doi.org/10.1126/science.6337396
Kamionka M (2011) Engineering of therapeutic proteins production in Escherichia coli. Curr Pharm Biotechnol 12:268–274. https://doi.org/10.2174/138920111794295693
Kane JF (1995) Effects of rare codon clusters on high-level expression of heterologous proteins in Escherichia coli. Curr Opin Biotechnol 6:494–500. https://doi.org/10.1016/0958-1669(95)80082-4
Lajoie MJ, Kosuri S, Mosberg JA, Gregg CJ, Zhang D (2013a) Church GM (2013) Probing the limits of genetic recoding in essential genes. Science 342:361–363. https://doi.org/10.1126/science.1241460
Lajoie MJ, Rovner AJ, Goodman DB, Aerni HR, Haimovich AD, Kuznetsov G, Mercer JA, Wang HH, Carr PA, Mosberg JA, Rohland N, Schultz PG, Jacobson JM, Rinehart J, Church GM, Isaacs FJ (2013b) Genomically recoded organisms expand biological functions. Science 342:357–360. https://doi.org/10.1126/science.1241459
Lau YH, Stirling F, Kuo J, Karrenbelt MAP, Chan YA, Riesselman A, Horton CA, Schäfer E, Lips D, Weinstock MT, Gibson DG, Way JC, Silver PA (2017) Large-scale recoding of a bacterial genome by iterative recombineering of synthetic DNA. Nucleic Acids Res 45:6971–6980. https://doi.org/10.1093/nar/gkx415
Lauber J, Handrick R, Leptihn S et al (2015) Expression of the functional recombinant human glycosyltransferase GalNAcT2 in Escherichia coli. Microb Cell Fact 14:3. https://doi.org/10.1186/s12934-014-0186-0
Lederberg, J (2004) E. coli K-12 Microbiology Today Vol 31 https://socgenmicrobiol.org.uk/pubs/micro_today/pdf/080402.pdf
Levy R, Weiss R, Chen G, Iverson BL, Georgiou G (2001) Production of correctly folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the coexpression of molecular chaperones. Protein Expr Purif 23:338–347. https://doi.org/10.1006/prep.2001.1520
Lipinszki Z, Vernyik V, Farago N, Sari T, Puskas LG, Blattner FR, Posfai G, Gyorfy Z (2018) Enhancing the translational capacity of E. coli by resolving the codon bias. ACS Syn Biol 7:2656–2664. https://doi.org/10.1021/acssynbio.8b00332
Liu Y (2020) A code within the genetic code: codon usage regulates co-translational protein folding. Cell Commun Signal 18:145. https://doi.org/10.1186/s12964-020-00642-6
Lobstein J, Emrich CA, Jeans C et al (2012) SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm. Microb Cell Fact 11:753. https://doi.org/10.1186/1475-2859-11-56
Macošek J, Mas G, Hiller S (2021) Redefining molecular chaperones as chaotropes. Front Mol Biosci 8:683132. https://doi.org/10.3389/fmolb.2021.683132
Mädje K, Schmölzer K, Nidetzky B, Kratzer R (2012) Host cell and expression engineering for development of an E. coli ketoreductase catalyst: enhancement of formate dehydrogenase activity for regeneration of NADH. Microb Cell Fact 11:7. https://doi.org/10.1186/1475-2859-11-7
Mirzadeh K, Shilling PJ, Elfageih R et al (2020) Increased production of periplasmic proteins in Escherichia coli by directed evolution of the translation initiation region. Microb Cell Fact 19:85. https://doi.org/10.1186/s12934-020-01339-8
Mital S, Christie G, Dikicioglu D (2021) Recombinant expression of insoluble enzymes in Escherichia coli: a systematic review of experimental design and its manufacturing implications. Microb Cell Fact 20:208. https://doi.org/10.1186/s12934-021-01698-w
Montero IG, Richards KL, Jawara C, Browning DF, Peswani AR, Labrit M, Allen M, Aubry C, Davé E, Humphreys DP, Busby SJ (2019) Escherichia coli “TatExpress” strains export several g/L human growth hormones to the periplasm by the Tat pathway. Biotechnol Bioeng 116:3282–3291. https://doi.org/10.1002/bit.27147
Mueller P, Gauttam R, Raab N et al (2018) High-level in vivo mucin-type glycosylation in Escherichia coli. Microb Cell Fact 17:168. https://doi.org/10.1186/s12934-018-1013-9
Mukai T, Hoshi H, Ohtake K et al (2015) Highly reproductive Escherichia coli cells with no specific assignment to the UAG codon. Sci Rep 5:9699. https://doi.org/10.1038/srep09699
Napolitano MG, Landon M, Gregg CJ, Lajoie MJ, Govindarajan L, Mosberg JA, Kuznetsov G, Goodman DB, Vargas-Rodriguez O, Isaacs FJ, Söll D, Church GM (2016) Emergent rules for codon choice elucidated by editing rare arginine codons in Escherichia coli. Proc Natl Acad Sci USA 113:E5588–E5597. https://doi.org/10.1073/pnas.1605856113
Nouri HR, Karkhah A, Varasteh A, Sankian M (2016) expression of a chimeric allergen with high rare codons content in codon bias-adjusted Escherichia coli: Escherichia coli BL21 (DE3)-codon plus ril as an efficient host. Curr Microbiol 73:91–98. https://doi.org/10.1007/s00284-016-1027-7
Ostrov N et al (2016) Design, synthesis, and testing toward a 57-codon genome. Science 353:819–822. https://doi.org/10.1126/science.aaf3639
Owens B (2017) Faster, deeper, smaller-the rise of antibody-like scaffolds. Nat Biotech 35:602–603. https://doi.org/10.1038/nbt0717-602
Park JS, Lee WC, Song JH, Kim SI, Lee JC, Cheong C, Kim HY (2013) Purification, crystallization and preliminary X-ray crystallographic analysis of diaminopimelate epimerase from Acinetobacter baumannii. Acta Crystallogr Sect F Struct Biol Cryst Commun 69:42–44. https://doi.org/10.1107/S1744309112048506
Reid JH, Durant KM, Chen SL, Perissinotti AJ, King R, Khoriaty R, Marini BL (2020) Role of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura. J Oncol Pharm Pract 26:1695–1702. https://doi.org/10.1177/1078155220934862
Ren G, Ke N, Berkmen M (2016) Use of the SHuffle Strains in Production of Proteins. Curr Protoc Protein Sci. 85:526.1–5.26.21. https://doi.org/10.1002/cpps.11.
Rettenbacher et al (2021) Microbial protein cell factories fight back? Trends in Biotech. https://doi.org/10.1016/j.tibtech.2021.10.003
Robertson WE, Funke LFH, de la Torre D et al (2021) Creating custom synthetic genomes in Escherichia coli with REXER and GENESIS. Nat Protoc 16:2345–2380. https://doi.org/10.1038/s41596-020-00464-3
Rosano GL, Ceccarelli EA (2014) Recombinant protein expression in Escherichia coli: advances and challenges. Front Microbiol 17:172. https://doi.org/10.3389/fmicb.2014.00172
Rosano GL, Morales ES, Ceccarelli EA (2019a) New tools for recombinant protein production in Escherichia coli: A 5-year update. Protein Sci 28:1412–1422. https://doi.org/10.1002/pro.3668
Rosano GL, Morales ES, Ceccarelli EA (2019b) New tools for recombinant protein production in Escherichia coli: A 5-year update. Prot Sci 28:1412–1422. https://doi.org/10.1002/pro.3668
Saaranen MJ, Ruddock LW (2019) Review applications of catalysed cytoplasmic disulphide bond formation. Biochem Soc Trans 47:1223–1231. https://doi.org/10.1042/BST20190088
Salis B, Spinetti G, Scaramuzza S, Bossi M, Saccani Jotti G, Tonon G et al (2015) High-level expression of a recombinant active microbial transglutaminase in Escherichia coli. BMC Biotechnol 15:84. https://doi.org/10.1186/s12896-015-0202-4
Sandomenico A, Sivaccumar JP, Ruvo M (2020) Evolution of Escherichia coli expression system in producing antibody recombinant fragments. Int J Mol Sci 21:6324. https://doi.org/10.3390/ijms21176324
Schjoldager KT, Narimatsu Y, Joshi HJ et al (2020) Global view of human protein glycosylation pathways and functions. Nat Rev Mol Cell Biol 21:729–749. https://doi.org/10.1038/s41580-020-00294-x
Schlegel S, Genevaux P, de Gier JW (2015) De-convoluting the genetic adaptations of E. coli C41(DE3) in real time reveals how alleviating protein production stress improves yields. Cell Rep 10:1758–1766. https://doi.org/10.1016/j.celrep.2015.02.029
Seinen AB, Spakman D, van Oijen AM et al (2021) Cellular dynamics of the SecA ATPase at the single molecule level. Sci Rep 11:1433. https://doi.org/10.1038/s41598-021-81081-2
Shiloach J, Reshamwala S, Noronha SB, Negrete A (2010) Analyzing metabolic variations in different bacterial strains, historical perspectives and current trends example E. coli. Curr Opin Biotechnol 21:21–26. https://doi.org/10.1016/j.copbio.2010.01.001
Simeon R, Chen Z (2018) In vitro-engineered non-antibody protein therapeutics. Prot Cell 9:3–14. https://doi.org/10.1007/s13238-017-0386-6
Singh SM, Panda AK (2005) Solubilization and refolding of bacterial inclusion body proteins. J Biosci Bioeng 99:303–310. https://doi.org/10.1263/jbb.99.303
Sohail AA, Gaikwad M, Khadka P, Saaranen MJ, Ruddock LW (2020) Production of extracellular matrix proteins in the cytoplasm of E. coli: making giants in tiny factories. Int J Mol Sci 21:688. https://doi.org/10.3390/ijms21030688
Tegel H, Ottosson J, Hober S (2011) Enhancing the protein production levels in Escherichia coli with a strong promoter. FEBS J 278:729–739. https://doi.org/10.1111/j.1742-4658.2010.07991.x
Tripathi NK, Shrivastava A (2019) Recent developments in bioprocessing of recombinant proteins: expression hosts and process development. Front Bioeng Biotechnol 7:420. https://doi.org/10.3389/fbioe.2019.00420
Vadala BS, Deshpande S, Apte-Deshpande A (2021) Soluble expression of recombinant active cellulase in E. coli using B. subtilis (natto strain) cellulase gene. J Genet Eng Biotechnol 19:7. https://doi.org/10.1186/s43141-020-00103-0
Valderrama-Rincon JD, Fisher AC, Merritt JH, Fan YY, Reading CA, Chhiba K, Heiss C, Azadi P, Aebi M, DeLisa MP (2012) An engineered eukaryotic protein glycosylation pathway in Escherichia coli. Nat Chem Biol 8:434–436. https://doi.org/10.1038/nchembio.921
Venetz JE, Del Medico L, Wölfle A, Schächle P, Bucher Y, Appert D, Tschan F, Flores-Tinoco CE, van Kooten M, Guennoun R, Deutsch S, Christen M, Christen B (2016) Chemical synthesis rewriting of a bacterial genome to achieve design flexibility and biological functionality. Proc Natl Acad Sci USA 116:8070–8079. https://doi.org/10.1073/pnas.1818259116
Waegeman H, De Lausnay S, Beauprez J, Maertens J, De Mey M, Soetaert W (2013) Increasing recombinant protein production in Escherichia coli K12K–12 through metabolic engineering. New Biotechnol 30:255–261. https://doi.org/10.1016/j.nbt.2011.11.008
Wagner S, Klepsch MM, Schlegel S, Appel A, Draheim R, Tarry M, Högbom M, van Wijk KJ, Slotboom DJ, Persson JO, de Gier JW (2008) Tuning Escherichia coli for membrane protein overexpression. Proc Natl Acad Sci USA 105:14371–14376. https://doi.org/10.1073/pnas.0804090105
Walsh G (2010) Biopharmaceutical benchmarks. Nat Biotechnol 28:917–924. https://doi.org/10.1038/nbt0910-917
Walsh G, Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24:1241–1252. https://doi.org/10.1038/nbt1252
Wang K, Fredens J, Brunner SF, Kim SH, Chia T, Chin JW (2016) Defining synonymous codon compression schemes by genome recoding. Nature 539:59–64. https://doi.org/10.1038/nature20124
Yoneda K, Fukuda J, Sakuraba H, Ohshima T (2010) First crystal structure of l-lysine 6-dehydrogenase as an NAD-dependent amine dehydrogenase. J Biol Chem 285:8444–8453. https://doi.org/10.1074/jbc.M109.084384
Zhou M, Wang T, Fu J, Xiao G, Liu Y (2015) Nonoptimal codon usage influences protein structure in intrinsically disordered regions. Mol Microbiol 97:974–987. https://doi.org/10.1111/mmi.13079
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflict of interest in this work.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
McElwain, L., Phair, K., Kealey, C. et al. Current trends in biopharmaceuticals production in Escherichia coli. Biotechnol Lett 44, 917–931 (2022). https://doi.org/10.1007/s10529-022-03276-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10529-022-03276-5